USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ADVANCED GENETIC SYSTEMS, INC.
Address:
1554 25TH AVE
SAN FRANCISCO, CA 94122-3320
Phone:
N/A
URL:
N/A
EIN:
132008058
DUNS:
154446921
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $518,562.00 2
STTR Phase I $685,387.00 2
STTR Phase II $820,375.00 1

Award List:

Genetic Assay for Inhibitors of RNA-Protein Interactions

Award Year / Program / Phase:
2003 / STTR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): RNA-protein interactions play critical roles in cellular regulatory processes and in the life cycles of many pathogenic viruses, including HIV, hepatitis C, and West Nile virus, and thus represent attractive targets for therapeutics. Much of our previous work has… More

Genetic Assay for Inhibitors of RNA-Protein Interactions

Award Year / Program / Phase:
2005 / STTR / Phase II
Award Amount:
$820,375.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
RI Contact:
N/A
Abstract:
RNA-protein interactions play critical roles in cellular regulatory processes and in the life cycles of many pathogenic viruses including HIV, hepatitis C, SARS, and West Nile virus, and thus represent attractive targets for therapeutics. We have developed novel cell-based assays to identify drugs… More

A small molecule screen to target viral RNA-protein complexes

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$238,974.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens. RNA-protein complexes represent an important and under utilized drug target. In HIV, the Tat-TAR an d Rev-RRE RNA- protein complexes carry out… More

Identification of Anti-HIV Lead Compounds Targeting Rev

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$585,387.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens. The Rev-RRE protein-RNA interaction in HIV plays an essential role in the transport of viral mRNA f rom the nucleus to the cytoplasm where it… More

Point of Care Device for Molecular Detection of HIV

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$279,588.00
Agency:
HHS
Principal Investigator:
Robert Nakamura – 415-806-0187
Abstract:
DESCRIPTION (provided by applicant): There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens. The Rev-RRE protein-RNA interaction in HIV plays an essential role in the transport of viral mRNA from the nucleus to the cytoplasm where it… More